lenalidomide,idecabtagene vicleucel
bms,2seventy bio
['bet', 'multiple myeloma', 'ide-cel', 'multiplemyeloma', 'karmma', 'karmma-2', 'idecabtagene', 'jints ']
excellent presentation by . promising outcomes in the karmma-2 trial of bcma cart cell therapy for #multiplemyeloma . orr of 84%, cr rate of 46%; mrd negativity sustained in those with a prolonged cr. #ash2022 
Associate Prof RadOnc @MDAndersonNews specializing in Heme Malignancies, Rad Onc Residency Program Director, wife, mom of 3,sister,daughter,friend. Tweets=mine